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UKAim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular
pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3–4
year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with
mumps-measles-rubella vaccine (MMRV).
Methods: This phase III, open label, randomised study was conducted in the UK between April 2011 and
April 2012. Children due their pre-school dTap-IPV booster vaccination were randomised 2:1 to receive
one of two different dTap-IPV vaccines (dTap-IPVB or dTap-IPVR) with blood sample for immunogenicity
assessment just prior and one month after vaccination. Immune responses to diphtheria, tetanus and
polio antigens were compared between the study vaccines (inferential comparison). In the absence of
an accepted pertussis correlate of protection, the immunogenicity of dTap-IPVB vaccine against pertussis
was compared with historical pertussis efficacy data (inferential comparison). Safety and reactogenicity
of both study vaccines were evaluated.
Results: 387 children were randomised and 385 vaccinated: 255 in the dTap-IPVB group and 130 in the
dTap-IPVR group. Prior to vaccination, 76.8% of children had anti-diphtheria and 65.5% had anti-
tetanus titres above the protection threshold; for pertussis, the pre-vaccination seropositivity rate ranged
between 18.1 and 70.6%. Both vaccines were immunogenic with 99.2–100% of children achieving titres
above the pre-specified seroprotection/seropositivity thresholds. One serious adverse event not consid-
ered as causally related to the study vaccination by the study investigator was reported in the dTap-
IPVB group.Tap-IPV,
cy; El.U/
s; IU/ml,
, year.
ail.com
ics.ox.ac.
R. Marlow et al. / Vaccine 36 (2018) 2300–2306 2301Conclusion: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically
acceptable safety and reactogenicity profile when co-administered with MMRV to children 3–4 years old.
Trial registration: NCT01245049 (ClinicalTrials.gov)
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The timing of primary and booster doses of diphtheria (d), teta-
nus (T), acellular pertussis (ap) and inactivated poliovirus (IPV)
varies widely across Europe [1]. Most countries give two or three
doses in the first six months (m) followed by one at 12–18 m (ter-
med 2 + 1/3 + 1 schedules) with a further booster before starting
school. However the UK schedule just has three infant doses with
no DTaP-IPV booster at 12–18 m; at this visit children already
receive four injections (Haemophilus influenzae type B, pneumococ-
cal conjugate, mumps-measles-rubella [MMR] and meningococcal
B). By three to five years of age the protection gained from primary
vaccinations in infancy is starting to wane [2] so the pre-school
booster is given between three and a half and four years. At this
age low dose diphtheria vaccines have been shown to induce ade-
quate immune responses but with the advantage of lower rates of
local side effects [3]. dTap-IPV (dTap-IPVB; Boostrix-IPV, GSK) is
already used as a pre-school booster in many countries around
the world but is licensed only from the age of four. The aim of this
study was to generate evidence to support the use of dTap-IPVB in
three to four year olds so it could potentially be used as a pre-
school booster vaccine at this age. Thus we aimed to demonstrate
that the immunogenicity of dTap-IPVB is not inferior to that of
dTap-IPVR (Repevax, Sanofi-Pasteur), the vaccine in routine use at
the time in the UK and which is approved for use in persons from
three years of age upwards. In the absence of accepted correlate of
protection for pertussis, the immunogenicity of dTap-IPVB was
evaluated by comparison with historical pertussis efficacy data
[4,5].
2. Methods
2.1. Study design and setting
We conducted an open-label, randomised, multicentre trial in
five paediatric research centres in the UK (Bristol, Exeter, Oxford,
Southampton and Taunton) and seven general practices. Ethical
approval was obtained from the South West 2 Research Ethics
Committee (NHS REC Ref: 10/H0206/43). The trial was registered
with the European Clinical Trials Database (2009-012202-39) and
ClinicalTrials.gov (NCT01245049).
2.2. Participants
Eligible participants were healthy children between three and
less than five years of age who had had their previous vaccines
on time as per national immunization program in the UK (three
diphtheria, tetanus, pertussis and polio doses primary schedule
completed before six months of age and first MMR vaccine before
two years of age) but had not already received their routine pre-
school dTap-IPV booster. Children were excluded from participat-
ing if they had a known allergy to the vaccine components, known
immunodeficiency, chronic use of steroids or were concurrently in
another clinical trial. Full exclusion criteria are listed in online
supplement (Supplementary Table 1). Families were recruited
either using postal mailings through local Child Health Databases
or from their general practices. Vaccination was postponed forany intercurrent febrile illness with axillary temperature 37.5 C
or other moderate to severe acute illness.
Co-primary objectives were to demonstrate, one month after
vaccination, non-inferiority of
(1) The immune responses to diphtheria, tetanus and polio anti-
gens induced by dTap-IPVB when compared to those induced
by dTap-IPVR.
(2) The immune response to pertussis antigens induced by
dTap-IPVB when compared to historical data relating to DTaP
vaccine (Infanrix vaccine, GSK) when administered to
infants.
Both study vaccines contained diphtheria (low amounts) and
tetanus toxoids, pertussis antigens (low amounts) and three polio
strains (vaccine composition is presented in Table 1). However
dTap-IPVB contained three of the five pertussis antigens in dTap-
IPVR at different doses. With no available immunological correlate
of protection for pertussis, it was felt that the most clinically rele-
vant comparator would be the historical immunogenicity [4] and
efficacy [5] data originally supporting the licensure of this combi-
nation of pertussis antigens. The study design and endpoints were
decided in liaison with the European Medicines Agency (EMA) to
meet requirements for Paediatric Investigation Plan approval.
2.3. Study procedures
After initial contact and eligibility checking, the study com-
prised two visits. At the first, written informed consent was
obtained from the parent/legal guardian. Children were then ran-
domised using GSK’s central Internet Randomisation system (SBIR)
(using a block size of six and a minimisation procedure accounting
for centre) and allocated to receive either dTap-IPVB (lots
AC39B034B, AC39B026A, AC39B032A1) or dTap-IPVR (lots DEX-
TA397AZ, DEXTA419AZ) in a 2:1 ratio as their pre-school dTap-
IPV booster with both groups also receiving a dose of MMR booster
(Priorix, GSK, Lots AMJRB892AZ, AMJRC160AZ, AD01B679C,
AD01B801A, AD01B733B). After randomisation, the study was
open label with both investigator and child’s parents aware of their
allocation. A blood sample (2.5 mls) was drawn before vaccination.
Vaccines were given intramuscularly dTap-IPV into the left deltoid,
MMR into right deltoid, using 25 mm 23 G needles, respectively.
Solicited local and general symptoms occurring within four days
following vaccination were recorded in diary cards as were other
(unsolicited) adverse events (AEs) occurring within 30 days of vac-
cination. Information on serious adverse events (SAEs) occurring at
any time-point during the study was also collected. The second and
final study visit was 30 days (range: 21–48 days) after the first visit
and comprised a second blood sample and collection of diary cards.
2.4. Laboratory assays
All assays were performed at the laboratories of GSK Biologicals
(Rixensart, Belgium) with laboratory staff blinded to the
participant group. Antibodies against diphtheria toxoid (anti-
diphtheria), tetanus toxoid (anti-tetanus) and pertussis compo-
nents (pertussis toxoid [PT], filamentous haemagglutinin [FHA]
Table 1
Comparison of vaccine components.
Vaccine Diphtheria
toxoid (IU)
Tetanus
toxoid (IU)
Pertussis antigens (mg) Polio antigens
(D-antigen
units)
Adjuvant
PT FHA PRN Fimbriae 2/3 1 2 3
dTap-IPVR 2 20 2.5 5 3 5 40 8 32 Aluminium phosphate: 0.33 mg Al3+
dTap-IPVB 2 20 8 8 2.5 – 40 8 32 Aluminium hydroxide and phosphate: 0.5 mg Al3+
DTaP 30 40 25 25 8 – – – – Aluminium hydroxide: 0.5 mg Al3+
IU, international units; PT, pertussis toxoid; FHA, filamentous haemagglutinin; PRN, pertactin; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-polio vaccine
(Boostrix); dTap-IPVR, reduced diphtheria-tetanus-acellular pertussis-polio vaccine (Repevax); DTaP, diphtheria-tetanus-acellular pertussis vaccine (Infanrix).
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immunosorbent assays (ELISA) developed in-house. Specific IgG
antibodies to measles, mumps and rubella were measured using
commercially available ELISAs following the manufacturers’
instructions (Dade Behring, Germany). For both anti-diphtheria
and tetanus thresholds for correlates of clinical protection were
defined as 0.1 international units per millilitre (IU/ml), three times
the lower quantification limit of the assays as previously demon-
strated [6,7]. With no established serological correlates of protec-
tion for pertussis antigens [8–10], measles [11], mumps [12] or
rubella, the thresholds for serological responses (positive: greater
than or equal) were arbitrarily defined as the lower limits of the
assays: 5 El.U/ml (all pertussis antigens), 150 mIU/ml, 231 U/ml
and 4 IU/ml, respectively. Seroconversion was defined as seropos-
itivity in the relevant assay in participants seronegative before vac-
cination. Antibody titres against poliovirus types 1, 2 and 3 were
determined by the manufacturer’s in-house virus micro-
neutralisation test standardized according to WHO guidance [13]
and were expressed as the reciprocal of the dilution resulting in
50% inhibition. Polio antibody titres greater than or equal to 1:8
dilution were considered seropositive and protective [14].
2.5. Statistics
2.5.1. Analysis of immunogenicity
The protocol pre-defined standard non-inferiority criteria [15].
For diphtheria and tetanus responses – the upper 95% confidence
interval (CI) limit of the (dTap-IPVR group minus dTap-IPVB group)
difference between the percentage of participants in the two
groups with post-vaccine antibody concentrations above the pre-
defined protective threshold was to be less than 10%; for poliovirus
types 1, 2 and 3 – the upper 95% CI limit of the ratio of geometric
mean titres (GMTs) (dTap-IPVR group divided by dTap-IPVB group)
was to be less than or equal to two and for pertussis antigens – the
upper 95% CI limit of the ratio of geometric mean concentrations
(GMCs) (historic DTaP data [4,5] divided by dTap-IPVB group in this
study) was to be less than or equal to 1.5.
Secondary objectives were to describe the immunogenicity of
both study vaccines in terms of seroprotection/seropositivity rates
and GMCs/GMTs for all antigens, prior to and one month after
booster vaccination; the percentage of participants with booster
response to the pertussis and polio antigens; to describe the
immune responses to the MMR vaccine in terms of seroconversion
rates against mumps, measles and rubella, one month after booster
vaccination; and to assess the safety and reactogenicity of the
study vaccines in terms of solicited symptoms, unsolicited AEs
and SAEs.
The primary analysis was based on the cohort of participants
who completed the study according to protocol (ATP) for analysis
of immunogenicity. If, in any vaccine group, the percentage of vac-
cinated participants with serological results excluded from this
ATP cohort was 5% or more, a second analysis of the total vacci-
nated cohort was to be performed to complement the ATP analysis.Given the absence of serologic correlates of protection against
pertussis, an immuno-bridging approach was used to assess
immune responses to pertussis antigens, by extrapolating the effi-
cacy of a vaccine against pertussis as demonstrated in infants to an
older age group, as previously described [16].
2.5.2. Safety
Safety and reactogenicity of the study vaccines were assessed in
terms of solicited symptoms (local and general), unsolicited symp-
toms and SAEs. The intensity of solicited symptoms was graded as
mild, moderate or severe (defined in Supplementary Table 2) and
assessment of causality by vaccination was assessed by investiga-
tors. Additionally, p values for the difference in proportion of par-
ticipants reporting the solicited symptom, and solicited and
unsolicited symptoms combined, were computed post hoc using
the continuity adjusted chi-square method. However, the results
should be interpreted with caution since there was no adjustment
for multiplicity.
2.5.3. Sample size
It was calculated that 230 participants in the dTap-IPVB group
and 115 in the dTap-IPVR group (a total of 345) would provide at
least 90% overall power to reach conclusions on all the co-
primary objectives simultaneously (with Bonferroni adjustment).
Assuming a dropout rate of 10%, a total of 384 participants (256
participants in dTap-IPVB group and 128 in dTap-IPVR group) was
chosen to ensure that a sufficient number of evaluable participants
was available for inclusion in the per protocol cohort for analysis of
immunogenicity. Statistical analysis was done by GSK with inde-
pendent statistical verification carried out by KJC statistics
(www.kjcstatistics.com).
3. Results
The study ran from April 2011 to April 2012. 387 children were
enrolled and 385 were vaccinated: 255 in dTap-IPVB arm, 130 in
dTap-IPVR group (Fig. 1). There were no significant differences in
baseline characteristics in the ATP immunogenicity cohort: in both
groups mean age at vaccination was 3.1 years with an equal pro-
portion of genders and similar heritage (Table 2). The ATP
immunogenicity cohort comprised 76.5%/73.8% (dTap-IPVB/dTap-
IPVR, respectively) of the total vaccinated cohort mainly due to
missing serological data through difficulties in obtaining blood
samples. As per protocol, an additional total vaccinated cohort
immunogenicity analysis was performed but found no significant
difference in primary or secondary outcomes – results are provided
as an online appendix (Supplementary Tables 3–5).
3.1. Immunogenicity results
For the study’s primary inferential analyses; at 30 days post
booster vaccination the non-inferiority criteria for the upper
bounds of the 95% CI of differences between comparator vaccines
Total enrolled
387
dTap-IPVB
255
(2 withdrew before 
vaccinaon)
dTap-IPVR
130 Total Vaccinated Cohort
254
(1 randomisaon failure)
130 ATP safety Cohort
195 (76%)
(6 protocol violaons)
(4 non-compliance)
(49 serology missing data)
96 (74%)
(4 protocol violaons)
(3 non-compliance)
(27 serology missing data)
ATP immunogenicity cohort
2:1 randomisaon
Fig. 1. Participant flow chart. ATP, according to protocol; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-polio vaccine (Boostrix-IPV); dTap-IPVR, reduced
diphtheria-tetanus-acellular pertussis-polio vaccine (Repevax).
Table 2
Demographic characteristics (ATP cohort for immunogenicity).
dTap-IPVB group
(N = 195)
dTap-IPVR group
(N = 96)
Age (years) at vaccination
Mean (SD) 3.1 (0.2) 3.1 (0.2)
Range (min–max) 3–4 3–4
Female/male, % 48.7/51.3 53.1/46.9
Heritage, n (%)
African/African American 1 (0.5) 3 (3.1)
Asian–Central/South Asian 3 (1.5) 4 (4.2)
Asian–South East Asian 2 (1.0) 0 (0)
White–Arabic/North African 1 (0.5) 0 (0)
White–Caucasian/European 175 (89.7) 84 (87.5)
Other 13 (6.7) 5 (5.2)
ATP, according to protocol; N, number of participants in each group; n, number of
participants in a given category; SD, standard deviation; min, minimum; max,
maximum; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-polio vaccine
(Boostrix-IPV); dTap-IPVR, reduced diphtheria-tetanus-acellular pertussis-polio
vaccine (Repevax).
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diphtheria and tetanus, and GMCs ratio for polio and pertussis
antigens) (Table 3).
For the secondary analyses the pre booster titres (Table 4)
showed that prior to boosting for all antigens a high proportion
of children in both groups had antibody levels below the defined
seroprotection/seropositivity thresholds; with 16.7–34.5% for
diphtheria and tetanus and 30.4–40.6% for polio. For pertussis
29.4–81.9% of participants had IgG titres below the pre-
determined optimal serological thresholds. For all antigens, 30
days post dTap-IPV booster vaccination the proportions of seropro-
tected/seropositive children had risen to >99% indicating adequate
serological response. Comparing antibody GMC/GMT between the
two study vaccines at one month post dTap-IPV vaccination(Table 4), marginally higher point estimates for diphtheria, tetanus,
Polio3 and PRN after dTap-IPVR vaccination, and marginally higher
point estimates for the Polio1, Polio2, PT and FHA after dTap-IPVB
vaccination were observed.
Prior to boosting, evidence of antibodies persistence for the
MMR vaccine (Table 4) was observed for at least 89.7% of children
meeting the immunological criteria for measles, mumps or rubella
in each group. One month after the MMR booster dose all children
had antibody titres above the defined immunological criteria with
no significant differences in GMTs between groups.3.2. Safety results
In the four day post vaccination period, 216/255 (84.7%; dTap-
IPVB) and 108/130 (83.1%; dTap-IPVR) (p = 0.79) of participants
reported at least one solicited symptom or unsolicited AE. For both
vaccines redness and pain were the most commonly reported. Sev-
ere (grade 3) symptoms were reported by a maximum of 11.0%
(redness in the dTap-IPVB group) and 18.4% (redness in the dTap-
IPVR group) (p = 0.08) of participants (Table 5).
During the 31-day (Days 0–30) post vaccination unsolicited
reporting period, 88/255 (34.5%; dTap-IPVB) and 36/130 (27.7%;
dTap-IPVR) (p = 0.22) of participants reported at least one AE of
which 4.7% and 4.6% (p = 1.0) respectively were considered to be
severe.
Diarrhoea and vomiting, reported for 9/255 (3.5%) participants
were the most frequently reported unsolicited AE in the dTap-IPVB
group while rash, reported for 6/130 (4.6%) participants was the
most frequently reported unsolicited AE in the dTap-IPVR group.
One SAE was reported during the whole clinical study duration;
pneumonia requiring hospitalisation reported for one participant
in the dTap-IPVB arm. This was felt not to be causally related to
vaccination by the investigator. No study participants withdrew
from the study due to an AE or SAE.
Table 3
Responses to vaccination and calculation of criteria for non-inferiority (inferential analyses).
Vaccine
antigen
Control*
data
(N) dTap-IPVB group
data
(N) Criteria for non-
inferiority
Control group minus dTap-IPVB group %
(95% CI)
Group response rate
(%)
Diphtheria 100 (90) 99.4 (177) 0.56% (3.55; 3.14) UL < 10%
Tetanus 100 (90) 98.3 (176) 1.70% (2.43; 4.90)
Control group/dTap-IPVB group
GMTs Polio 1 1983.1 (63) 2175.6 (131) 0.91 (0.65; 1.28) UL < 2
Polio 2 2168.7 (61) 2796.9 (100) 0.78 (0.54; 1.12)
Polio 3 4522.5 (68) 3468.8 (126) 1.30 (0.93; 1.84)
DTaP-APV039/dTap-IPVB group
GMCs (El.U/ml) PT 45.7 (2884) 69.8 (203) 0.65 (0.59; 0.72) UL < 1.5
FHA 83.6 (685) 362.1 (204) 0.23 (0.20; 0.27)
PRN 112.3 (631) 148.6 (204) 0.76 (0.64; 0.89)
The group difference in booster response to the diphtheria and tetanus antigens and the adjusted GMT ratios between groups for the poliovirus types 1, 2 and 3 antigens, one
month post-booster vaccinations are based on the according-to-protocol cohorts. The GMC ratios between groups for the anti-PT, anti-FHA and anti-PRN antigens one month
post-booster vaccination is based on the total vaccinated cohort. *Control data represent the data from the dTap-IPVR group for diphtheria, tetanus and polio types 1, 2 and 3
antigens, and from the DTaP-APV039 study for the pertussis antigens (PT, FHA and PRN). Bold values represent that the statistical criterion for non-inferiority was met.
CI, confidence interval; GMC, geometric mean concentration; GMT, geometric mean titre adjusted for baseline titre; El.U/ml, Enzyme-Linked Immunosorbent Assay units per
millilitre; UL, upper limit of the 95% confidence interval; N, number of participants with pre- and post-vaccination results available; PT, pertussis toxoid; FHA, filamentous
haemagglutinin; PRN, pertactin; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-polio vaccine (Boostrix-IPV); dTap-IPVR, reduced diphtheria-tetanus-acellular
pertussis-polio vaccine (Repevax); DTaP, diphtheria-tetanus-acellular pertussis vaccine (Infanrix).
Table 4
According to protocol pre-post vaccination serology results as proportion above serological threshold and pre-post vaccination geometric mean concentrations/titres (descriptive
analyses).
Vaccine antigen dTap-IPVB group dTap-IPVR group
Pre (95%CI) Post (95%CI) Pre (95%CI) Post (95%CI)
Diphtheria (% 0.1 IU/ml) 76.8 (69.9–82.8) 100 (98.1–100) 83.3 (74.0–90.4) 100 (96.2–100)
(GMC IU/ml) 0.228 (0.194–0.267) 8.113 (7.259–9.068) 0.259 (0.209–0.320) 11.948 (10.003–14.271)
Tetanus (% 0.1 IU/ml) 65.5 (58.0–72.5) 100 (98.1–100) 70.0 (59.4–79.2) 100 (96.2–100)
(GMC IU/ml) 0.209 (0.173–0.253) 6.787 (5.961–7.727) 0.241 (0.184–0.315) 9.194 (7.565–11.175)
Pertussis PT (% 5 El.U/ml) 18.1 (12.7–24.7) 100 (98.1–100) 20.0 (12.3–29.8) 100 (96.2–100)
(GMC El.U/ml) 3.4 (3.0–3.9) 70.1 (62.2–79.0) 3.2 (2.9–3.6) 47.8 (39.9–57.3)
FHA (% 5 El.U/ml) 64.4 (56.8–71.5) 100 (98.1–100) 70.6 (59.7–80.0) 100 (96.2–100)
(GMC El.U/ml) 12.9 (10.0–16.6) 358.3 (312.5–410.8) 10.7 (7.9–14.5) 164.8 (138.5–196.1)
PRN (% 5 El.U/ml) 34.9 (27.8–42.4) 99.5 (97.2–100) 40.7 (30.5–51.5) 100 (96.2–100)
(GMC El.U/ml) 4.3 (3.8–5.0) 151.4 (127.5–179.6) 4.3 (3.7–5.0) 209.8 (168.5–261.3)
Polio 1 (% 8 ED50) 59.4 (51.3–67.1) 99.4 (96.5–100) 63.6 (51.9–74.3) 100 (95.2–100)
(GMT ED50) 12.8 (10.6–15.5) 2183.3 (1812.4–2630.1) 13.2 (10.2–17.1) 1876.1 (1472.8–2389.7)
2 (% 8 ED50) 68.6 (60.7–75.7) 99.2 (95.6–100) 69.6 (58.2–79.5) 100 (94.9–100)
(GMT ED50) 15.5 (12.8–18.8) 2693.1 (2176.3–3332.5) 14.6 (11.3–18.8) 2203.8 (1681.0–2889.4)
3 (% 8 ED50) 64.1 (56.0–71.6) 99.4 (96.5–100) 59.5 (47.9–70.4) 100 (95.5–100)
(GMT ED50) 15.4 (12.7–18.8) 3762.4 (3080.9–4594.6) 14.5 (10.4–20.1) 4185.1 (3318.3–5278.3)
Measles (% 150 mIU/ml) 97.5 (93.7–99.3) 100 (97.3–100) 97.4 (90.8–99.7) 100 (94.7–100)
GMC mIU/mL 2644.0 (2261.3–3091.6) 3817.7 (3422.3–4258.8) 2702.6 (2146.0–3403.6) 3798.0 (3262.6–4421.1)
Mumps % 231 U/ml 89.7 (83.9–94.0) 100 (97.3–100) 90.8 (81.9–96.2) 100 (94.7–100)
GMC U/mL 1035.3 (869.8–1232.3) 6801.9 (6155.0–7516.8) 971.7 (752.1–1255.5) 6219.4 (5365.8–7208.8)
Rubella % 4 IU/ml 100 (97.7–100) 100 (97.3–100) 100 (95.3–100) 100 (94.7–100)
GMC IU/mL 66.5 (59.1–74.8) 134.3 (120.7–149.4) 72.6 (59.8–88.1) 130.3 (111.7–152.0)
CI, confidence interval; GMC, geometric mean concentration; GMT, geometric mean titre; El.U/ml, Enzyme-Linked Immunosorbent Assay units per millilitre; IU/ml, inter-
national units per millilitre; ED50, median effective dose; mIU/ml, milli-international units per millilitre; MMR, mumps-measles-rubella; N, number of participants with
available results; PT, pertussis toxoid; FHA, filamentous haemagglutinin; PRN, pertactin; U/ml, units per millilitre; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-
polio vaccine (Boostrix-IPV); dTap-IPVR, reduced diphtheria-tetanus-acellular pertussis-polio vaccine (Repevax); pre, pre-booster vaccination blood sampling; post, post-
booster vaccination blood sampling.
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This study compares the immunogenicity and AEs of two alter-
native dTap-IPV vaccines for use as a pre-school booster in the UK
vaccine schedule. According to the primary outcomes, the study
vaccine response was non-inferior to its comparator at one month
post-vaccination – both vaccines boosting serological responses
above accepted thresholds. There were no significant differences
in solicited or unsolicited local reactions between the two vaccines,
with mild redness and pain reported in 49.8–58.4% of cases.In this study which followed the UK infant schedule in use at
that time, we found that by the age of three and a half years, almost
a third of children had antibody levels that had waned below
desired levels for at least one vaccine component (Table 4) – rein-
forcing the requirement for a pre-school booster. This is in line
with a previous study showing serological evidence of protection
from UK primary course DTaP had substantially waned by the
age of three to -four years [17].
For diphtheria, although post-booster all children had anti-
body levels above threshold, GMCs were marginally higher for
Table 5
Solicited local and general symptom rates for each vaccine in first 4 days after vaccination as both percentage and absolute number of participants.
All reactions Severe (Grade 3) reactions
dTap-IPVB group (N = 255) dTap-IPVR group (N = 125) p dTap-IPVB group (N = 255) dTap-IPVR group (N = 125) p
Pain, % (n) 49.8 (127) 56.0 (70) 0.30 1.2 (3) 4.8 (6) 0.07
Redness, % (n) 57.3 (146) 58.4 (73) 0.92 11.0 (28) 18.4 (23) 0.07
Swelling, % (n) 36.1 (92) 42.4 (53) 0.28 7.1 (18) 13.6 (17) 0.06
Irritability, % (n) 42.0 (107) 39.2 (49) 0.69 1.6 (4) 0.8 (1) 0.89
Drowsiness, % (n) 30.2 (77) 31.2 (39) 0.94 1.6 (4) 0.8 (1) 0.89
Loss of appetite, % (n) 26.3 (67) 24 (30) 0.72 2.4 (6) 2.4 (3) 1.00
Fever, % (n) 7.1 (18) 7.2 (9) 1.00 1.6 (4) 0.8 (1) 0.89
Number in brackets represents the number of cases.
N, number of participants with available results; n, number of participants reporting the symptom; dTap-IPVB, reduced diphtheria-tetanus-acellular pertussis-polio vaccine
(Boostrix-IPV); dTap-IPVR, reduced diphtheria-tetanus-acellular pertussis-polio vaccine (Repevax). p values or the difference in proportion of participants reporting the
solicited symptom, and solicited and unsolicited symptoms combined, were computed using the continuity adjusted chi-square method. However, the results should be
interpreted with caution since there was no adjustment for multiplicity.
Severe (Grade 3) reactions were defined as: Pain (Cried when limb was moved/spontaneously painful), Swelling/Redness (>20 mm in diameter), Irritability (Crying that could
not be comforted/prevented normal activity), Drowsiness (Drowsiness that prevented normal activity), Loss of appetite (Did not eat at all), Fever (axillary temperature >39.0 C).
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considered protective. Due to the long half–life of these antibodies,
this degree of boosting above the protective threshold has been
shown to remain clinically effective for ten years, based on a
mathematical model [18].
With no agreed immunological correlate of protection against
pertussis, it was not appropriate to simply compare the antibody
response between the two study vaccines because dTap-IPVR con-
tains two additional pertussis antigens. Accordingly, our pre-
defined primary analysis was to compare the immune responses
to the booster dose of dTap-IPVB given in this study against histor-
ical immunogenicity data from the original study that demon-
strated clinical effectiveness for this combination of antigens.
This primary analysis showed non-inferiority. In a secondary anal-
ysis we compared the GMCs for the antigens common to both vac-
cines. All titres were significantly boosted but, as might be
expected, with minor difference between the vaccines. GMCs for
PT and FHA were higher for dTap-IPVB than dTap-IPVR, while the
reverse was true for PRN. Clearly both vaccines used as boosters
can provide a serological response. However even with adequate
pertussis vaccine responses, data from the US have shown rapid
waning of clinical protection (27% per year after the fifth dose of
pertussis vaccine) [19] leading the US to introduce an adolescent
booster dose for pertussis [20]. Further investigations would need
to be done to determine if the additional pertussis antigen con-
tained in dTap-IPVR resulted in any significant difference in the
rate of waning between the vaccines.
The limitation of this study is that whilst randomised, because
of the difference in the visual aspects of the study vaccines, the
study was designed to be open label. This meant that for AE record-
ing the parents were not blinded to the study arm – despite this
there were no significant differences between AE outcomes. Since
the study the UK infant vaccine schedule has changed with the
introduction of the rotavirus and meningococcal B immunisation
programmes. In response to rising rates of neonatal pertussis, in
2012 the UK introduced maternal dTap vaccination at 28–32
weeks gestation. This has been highly successful with significant
reduction in the number of cases [21]. However there is some evi-
dence that increased maternal titres may adversely affect early
infant vaccine responses [22,23], increasing the importance of an
effective the pre-school booster.
In conclusion, we found dTap-IPVB to be non-inferior to dTap-
IPVR with all children making an equivalent immune response after
boosting indicative of protection being afforded at the same level
as demonstrated now in the population as monitored by national
surveillance systems. There were minor differences betweenvaccines for individual antigens but these are unlikely to be of
any clinical significance.
Trademark statement
Boostrix-IPV, Infanrix and Priorix are trademarks of the GSK
group of companies. Repevax is a trade mark of Sanofi-Pasteur.
Funding
This study and related publication were sponsored by
GlaxoSmithKline Biologicals SA.
Acknowledgements
The authors thank all of the participants, their families and the
study staff at the research centres in the different participating
countries for contributing to this study. The authors also thank
Iudit-Hajnal Filip (XPE Pharma & Science, Wavre, Belgium c/o
GSK) for publication coordination.
Declaration of interest
R. Marlow declares receiving conference travel expenses from
GSK group of companies in 2014.
A. Finn received grants paid to his institution from Novartis
(Novartis Vaccines Division was subsequently acquired by the
GSK group of companies), GSK group of companies and Sanofi Pas-
teur MSD for studies outside the submitted work. Owing to his
membership on the Joint Committee on Vaccination and Immuni-
sation for the United Kingdom Department of Health, Adam Finn
no longer gives lectures or undertakes advisory work for industry,
either paid or unpaid.
M. Snape reports grants from GSK group of companies, Novartis,
Johnson and Johnson, MedImmune where he acted as investigator
for clinical vaccine studies; speaker fees from Novartis; and consul-
tancy fees from MedImmune.
A.J. Pollard reports previous grants from Pfizer and Okairos in
the past 36 months. His department received unrestricted educa-
tional grants from Pfizer/GSK/Astra Zeneca in July 2016 and
Gilead/MSD/GSK/Astra Zeneca in June 2017 for a course on Infec-
tion and Immunity in Children. A.J. Pollard is chair of the UK
Department of Health’s (DH) Joint Committee on Vaccination and
Immunization (JCVI) and the scientific advisory group on vaccines
for the European Medicines Agency and is a member of the WHO’s
2306 R. Marlow et al. / Vaccine 36 (2018) 2300–2306SAGE; the views presented in this manuscript do not necessarily
represent the views of DH JCVI, EMA or WHO.
S.N. Faust reports grants from GSK group of companies; S.N.
Faust has been advisory board member to vaccine and antimicro-
bial manufacturers (GSK, AstraZeneca, Pfizer, Novartis, Sanofi, Cub-
ist Pharmaceuticals, Actelion Pharmaceuticals, Astellas, Merck).
M. Snape, A. Pollard, S.N. Faust and R. Tomlinson declare that all
honoraria and fees were paid to the employing institution and no
personal fee or honoraria of any kind were received at any time.
S. Kuriyakose and N. Mesaros declare they are employed by the
GSK group of companies; N. Mesaros holds shares in the GSK group
of companies. H.H. Han was a GSK employee at the time the study
was conducted; she is now employee of Takeda Pharmaceuticals.
R. Tomlinson declares receipt of recruitment fees from GSK; all
honoraria were paid to the employing institution (Royal Devon &
Exeter NHS Trust) and no personal fee or honoraria of any kind
were received at any time.Authors’ contributions
R. Marlow, A. Finn, A.J. Pollard, S.N. Faust, M. Snape, S. Kuriya-
kose were involved in the conception and design of the study; R.
Marlow, A. Finn, A.J. Pollard, M. Snape, S.N. Faust, R. Tomlinson,
S. Kuriyakose, N. Mesaros and H.H. Han were involved in data
acquisition, analysis or interpretation. R. Marlow produced the first
draft of the manuscript, all authors revised the work critically,
approved the final version to be published and take full account-
ability for all aspects of the work.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.03.
021.
References
[1] European Centre of Disease Prevention and Control. European vaccine
schedules n.d. <http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.
aspx> [accessed April 15, 2015].
[2] Collins CL, Salt P, McCarthy N, Chantler T, Lane L, Hemme F, et al.
Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular
pertussis combination vaccine with either inactivated or oral polio vaccine as a
pre-school booster in UK children. Vaccine 2004;22:4262–9. https://doi.org/
10.1016/j.vaccine.2004.04.027.
[3] Tiwari TSP, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit
PA, editors. Vaccines, 6th ed. London: W.B. Saunders; 2013, p. 153–66.
10.1016/B978-1-4557-0090-5.00024-0.
[4] Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, et al.
Clinical experience of a tricomponent acellular pertussis vaccine combined
with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.
J Pediatr 1996;129:695–701.
[5] Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann
H, et al. Efficacy of acellular pertussis vaccine in early childhood after
household exposure. JAMA 1996;275:37–41.[6] Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic
assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol
1984;20:772–4.
[7] Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked
immunosorbent assay (ELISA) with the toxin neutralization test in mice as a
method for the estimation of tetanus antitoxin in human sera. J Biol Stand
1983;11:137–44.
[8] GranströmM, Thorén M, BlennowM, Tiru M, Sato Y. Acellular pertussis vaccine
in adults: adverse reactions and immune response. Eur J Clin Microbiol
1987;6:18–21.
[9] Sato Y, Izumiya K, Sato H, Cowell JL, Manclark CR. Role of antibody to
leukocytosis-promoting factor hemagglutinin and to filamentous
hemagglutinin in immunity to pertussis. Infect Immun 1981;31:1223–31.
[10] Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the
quantitation of serum immunoglobulin levels using the enzyme-linked
immunosorbent assay (ELISA). J Immunol Methods 1987;103:189–94.
[11] Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV. Comparison of
measles antihemolysin test, enzyme-linked immunosorbent assay, and
hemagglutination inhibition test with neutralization test for determination
of immune status. J Clin Microbiol 1985;22:296–8.
[12] Leinikki PO, Shekarchi I, Tzan N, Madden DL, Sever JL. Evaluation of enzyme-
linked immunosorbent assay (ELISA) for mumps virus antibodies. Proc Soc Exp
Biol Med 1979;160:363–7.
[13] WHO Expanded Programme on Immunization. Guidelines for WHO/EPI
collaborative studies on poliomyelitis: standard procedure for determining
immunity to poliovirus using the microneutralization test; 1993.
[14] World Health Organization. WHO expert committee on biological
standardization. Sixty-fifth report. World Health Organ Tech Rep Ser
2015;993:1–262.
[15] Horne AD, Lachenbruch PA, Getson PR, Hsu HS. Analysis of studies to evaluate
immune response to combination vaccines. Clin Infect Dis 2001;33:S306–11.
https://doi.org/10.1086/322566.
[16] Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR.
Acellular pertussis vaccine booster combined with diphtheria and tetanus
toxoids for adolescents. Pediatrics 2006;117:1084–93. https://doi.org/
10.1542/peds.2005-1759.
[17] Kitchin N, Southern J, Morris R, Borrow R, Fiquet A, Boisnard F, et al. Antibody
persistence in UK pre-school children following primary series with an
acellular pertussis-containing pentavalent vaccine given concomitantly with
meningococcal group C conjugate vaccine, and response to a booster dose of
an acellular pertussis-containing quadrivalent vaccine. Vaccine
2009;27:5096–102. https://doi.org/10.1016/j.vaccine.2009.06.049.
[18] Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter J, Schuerman L. Anti-
diphtheria antibody seroprotection rates are similar 10 years after vaccination
with dTpa or DTPa using a mathematical model. Vaccine 2004;23:336–42.
https://doi.org/10.1016/j.vaccine.2004.06.012.
[19] Klein NP, Bartlett J, Fireman B, Aukes L, Buck PO, Krishnarajah G, et al. Waning
protection following 5 doses of a 3-component diphtheria, tetanus, and
acellular pertussis vaccine. Vaccine 2017;35:3395–400. https://doi.org/
10.1016/j.vaccine.2017.05.008.
[20] America Academy of Pediatrics Commitee on Infectious Diseases. Prevention
of pertussis among adolescents: recommendations for use of tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics
2006;117:965–78. https://doi.org/10.1542/peds.2005-3038.
[21] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al.
Effectiveness of maternal pertussis vaccination in England: an observational
study. Lancet 2014;384:1521–8. https://doi.org/10.1016/S0140-6736(14)
60686-3.
[22] Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA,
et al. Antibody responses after primary immunization in infants born to
women receiving a pertussis-containing vaccine during pregnancy: single arm
observational study with a historical comparator. Clin Infect Dis
2015;61:1637–44. https://doi.org/10.1093/cid/civ695.
[23] Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O’Brien KL, Perera R, et al.
The influence of maternally derived antibody and infant age at vaccination on
infant vaccine responses: an individual participant meta-analysis. JAMA
Pediatr 2017;171:637–46. https://doi.org/10.1001/jamapediatrics.2017.0638.
